FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165886151> ?p ?o ?g. }

• W3165886151 endingPage "474" @default.
• W3165886151 startingPage "465" @default.
• W3165886151 abstract "To compare the pharmacokinetic profiles, safety and immunogenicity of proposed bevacizumab biosimilar HLX04 with reference bevacizumab in healthy Chinese males.In this double-blind Phase 1 study, healthy volunteers (N = 208) were randomized 1:1:1:1 to a single 3 mg/kg intravenous infusion of HLX04 or reference bevacizumab sourced from the United States (bevacizumab-US), the European Union (bevacizumab-EU) or China (bevacizumab-CN). Co-primary endpoints were area under the serum concentration-time profile (AUC) from time zero extrapolated to infinity (AUC0-inf) and from zero to last quantifiable concentration (AUClast). Secondary endpoint was the maximum serum drug concentration (Cmax). Study participants were monitored for treatment-emergent adverse events (TEAEs) and samples were collected for anti-drug antibody (ADA) testing throughout the study.Pharmacokinetic parameters were similar across groups. The respective geometric least-squares mean ratios (GLSMR) of AUC0-inf, AUClast and Cmax were: 95.7%, 96.0% and 101.8% for HLX04 versus bevacizumab-US; 94.3%, 94.6% and 100.5% for HLX04 versus bevacizumab-EU; and 90.0%, 90.4% and 98.2% for HLX04 versus bevacizumab-CN. For all test-to-reference comparisons, two-sided 90% confidence intervals of GLSMR for AUC0-inf, AUClast and Cmax fell in the pre-specified bioequivalence range (80-125%). There were no notable differences in the frequency, nature and/or grade of TEAEs. No deaths were reported and no ADAs were detected during the study.HLX04 had similar safety and pharmacokinetic profiles to reference bevacizumab in healthy Chinese males, supporting the confirmatory Phase 3 study investigating the efficacy and safety equivalence between HLX04 and bevacizumab in patients with metastatic colorectal cancer (NCT03511963).The study was registered with Clinicaltrials.gov, NCT03483649." @default.
• W3165886151 created "2021-06-07" @default.
• W3165886151 creator A5024098264 @default.
• W3165886151 creator A5049038852 @default.
• W3165886151 creator A5055344461 @default.
• W3165886151 creator A5057603213 @default.
• W3165886151 creator A5058246931 @default.
• W3165886151 creator A5072517057 @default.
• W3165886151 creator A5076636013 @default.
• W3165886151 creator A5080144369 @default.
• W3165886151 creator A5086032916 @default.
• W3165886151 date "2021-06-04" @default.
• W3165886151 modified "2023-09-24" @default.
• W3165886151 title "A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers" @default.
• W3165886151 cites W2062756251 @default.
• W3165886151 cites W2068014745 @default.
• W3165886151 cites W2077603264 @default.
• W3165886151 cites W2154200023 @default.
• W3165886151 cites W2298790377 @default.
• W3165886151 cites W2589671537 @default.
• W3165886151 cites W2732889090 @default.
• W3165886151 cites W2752880203 @default.
• W3165886151 cites W2811001329 @default.
• W3165886151 cites W2883744750 @default.
• W3165886151 cites W2889496401 @default.
• W3165886151 cites W2892127387 @default.
• W3165886151 cites W2893646688 @default.
• W3165886151 cites W2901574652 @default.
• W3165886151 cites W2911388614 @default.
• W3165886151 cites W2916186321 @default.
• W3165886151 cites W2921716909 @default.
• W3165886151 doi "https://doi.org/10.1007/s00280-021-04297-z" @default.
• W3165886151 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8316231" @default.
• W3165886151 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34086067" @default.
• W3165886151 hasPublicationYear "2021" @default.
• W3165886151 type Work @default.
• W3165886151 sameAs 3165886151 @default.
• W3165886151 citedByCount "5" @default.
• W3165886151 countsByYear W31658861512022 @default.
• W3165886151 countsByYear W31658861512023 @default.
• W3165886151 crossrefType "journal-article" @default.
• W3165886151 hasAuthorship W3165886151A5024098264 @default.
• W3165886151 hasAuthorship W3165886151A5049038852 @default.
• W3165886151 hasAuthorship W3165886151A5055344461 @default.
• W3165886151 hasAuthorship W3165886151A5057603213 @default.
• W3165886151 hasAuthorship W3165886151A5058246931 @default.
• W3165886151 hasAuthorship W3165886151A5072517057 @default.
• W3165886151 hasAuthorship W3165886151A5076636013 @default.
• W3165886151 hasAuthorship W3165886151A5080144369 @default.
• W3165886151 hasAuthorship W3165886151A5086032916 @default.
• W3165886151 hasBestOaLocation W31658861511 @default.
• W3165886151 hasConcept C105639569 @default.
• W3165886151 hasConcept C112705442 @default.
• W3165886151 hasConcept C126322002 @default.
• W3165886151 hasConcept C144133560 @default.
• W3165886151 hasConcept C168563851 @default.
• W3165886151 hasConcept C197934379 @default.
• W3165886151 hasConcept C203092338 @default.
• W3165886151 hasConcept C22979827 @default.
• W3165886151 hasConcept C2776694085 @default.
• W3165886151 hasConcept C2777802072 @default.
• W3165886151 hasConcept C2910001868 @default.
• W3165886151 hasConcept C42404028 @default.
• W3165886151 hasConcept C71924100 @default.
• W3165886151 hasConcept C98274493 @default.
• W3165886151 hasConceptScore W3165886151C105639569 @default.
• W3165886151 hasConceptScore W3165886151C112705442 @default.
• W3165886151 hasConceptScore W3165886151C126322002 @default.
• W3165886151 hasConceptScore W3165886151C144133560 @default.
• W3165886151 hasConceptScore W3165886151C168563851 @default.
• W3165886151 hasConceptScore W3165886151C197934379 @default.
• W3165886151 hasConceptScore W3165886151C203092338 @default.
• W3165886151 hasConceptScore W3165886151C22979827 @default.
• W3165886151 hasConceptScore W3165886151C2776694085 @default.
• W3165886151 hasConceptScore W3165886151C2777802072 @default.
• W3165886151 hasConceptScore W3165886151C2910001868 @default.
• W3165886151 hasConceptScore W3165886151C42404028 @default.
• W3165886151 hasConceptScore W3165886151C71924100 @default.
• W3165886151 hasConceptScore W3165886151C98274493 @default.
• W3165886151 hasIssue "3" @default.
• W3165886151 hasLocation W31658861511 @default.
• W3165886151 hasLocation W31658861512 @default.
• W3165886151 hasLocation W31658861513 @default.
• W3165886151 hasOpenAccess W3165886151 @default.
• W3165886151 hasPrimaryLocation W31658861511 @default.
• W3165886151 hasRelatedWork W1972752819 @default.
• W3165886151 hasRelatedWork W1989480569 @default.
• W3165886151 hasRelatedWork W2003476460 @default.
• W3165886151 hasRelatedWork W2008610508 @default.
• W3165886151 hasRelatedWork W2104641112 @default.
• W3165886151 hasRelatedWork W2354680669 @default.
• W3165886151 hasRelatedWork W2359939078 @default.
• W3165886151 hasRelatedWork W2365455541 @default.
• W3165886151 hasRelatedWork W2411695865 @default.
• W3165886151 hasRelatedWork W3089081291 @default.
• W3165886151 hasVolume "88" @default.
• W3165886151 isParatext "false" @default.
• W3165886151 isRetracted "false" @default.

• next